Venrock Buys $37.7M of Lycia Stock After IPO, Converting Preferred
LYCA sits 18% above its 52-week low of $22.19 on light trading volume (0.3× avg).
Summary
Between October 23 and October 27, 2026, Venrock funds bought 2,045,440 Lycia shares for $37.7 million and converted Series C and D preferred into 4,779,793 common shares at the IPO closing.
Key Events · Ownership and Investor Activity · LYCA
-
Venrock Buys $37.7M Post-IPO
Across six transactions from 2026-10-23 to 2026-10-27, Venrock healthcare funds purchased 2,045,440 common shares for $37,653,863.
-
Purchases Priced $18.00-$26.97
Weighted-average prices ranged from $18.00 (the IPO price) to $26.97, meaning the sponsor bought both at the deal price and in the aftermarket above it.
-
Preferred Converts at IPO Close
At the IPO closing on 2026-10-26, Series C and Series D preferred converted into 4,779,793 common shares on a one-for-0.221793422 basis, with no consideration paid.
-
Holdings Reach 6,825,233 Shares
Post-transaction indirect holdings via the Venrock funds total 6,825,233 shares; the reporting persons are 10% owners, not officers or directors.
Analysis · LYCA · Life Sciences
Why it matters: Venrock's healthcare funds put $37.7 million to work buying Lycia shares in the open market over the first three trading days after the IPO, on top of converting their preferred into common stock. The purchases ranged from $18.00 (the IPO price) up to $26.97, so the sponsor kept adding exposure even as the stock traded well above the offering price. That is real money from a large existing holder right after the deal, not a mechanical exercise or grant.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LYCA was trading at $26.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $22.19 to $36.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.